
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Xspray Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dasatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Xspray Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
